5:57 PM
 | 
Oct 10, 2012
 |  BC Extra  |  Company News

Oxford discontinues U.S. TroVax prostate cancer trial

Oxford BioMedica plc (LSE:OXB) stopped a U.S. Phase II trial of TroVax in patients with metastatic hormone-refractory prostate cancer (HRPC) due to slower-than-expected patient recruitment. Oxford attributed the slow enrollment to changes in the prostate cancer space since...

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >